GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing preventive and therapeutic human vaccines and immunotherapies against infectious diseases and cancer. The Company recently significantly expanded its clinical stage portfolio through the in-licensing of two Phase 2 products/programs within SARS-CoV-2 and Head & Neck Cancer immunotherapy. The Company’s proprietary GV-MVA-VLP™ vector vaccine technology utilizes a Modified Vaccinia Ankara (MVA) vector, a large virus capable of carrying several vaccine antigens, which are expressed as non-infectious virus-like particles (VLPs) in the individual receiving the vaccine (in vivo). VLPs mimic a natural infection, stimulating both the humoral (antibody) and cellular (T-cells) arms of the immune system to recognize, prevent, and control the target infection through durable immune responses. In addition to the GV-MVA-VLP™ technology, the recent license of the SARS-CoV-2 vaccine (GEO/COH04S1) provides the Company a complementary technology, sMVA (synthetic MVA), and the license of Gedeptin® adds the GDEPT (Gene Directed Enzyme Prodrug Therapy) technology to the GeoVax technology platform portfolio. GeoVax is capitalizing on these technologies and its vaccine/immunotherapy design expertise to address the need for a broadly effective COVID-19 vaccine. The Company is also developing vaccines against Zika virus (ZIKV), hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa Fever), and malaria, while also applying its MVA-VLP™ technology to cancer immunotherapy (immuno-oncology).
* The Corporate Snapshot was last updated on March 15, 2022.